Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Office of Regulatory Affairs

Office of Regulatory Affairs

                        FDA/ORA Efforts to Ensure Product Safety
          ORA Recruitment Handouts
          Jobs at the Office of Regulatory Affairs (ORA)
          Office of Regulatory Affairs Senior Executive Team


                        ORA Program Areas
          Regulatory News, Stories, and Features
          Contact ORA
          ORA FOIA Electronic Reading Room Home
          About FDA
          FDA Organization
          Office of Regulatory Affairs
          FDA/ORA Efforts to Ensure Product SafetyOffice of Regulatory Affairs FDA/ORA Efforts to Ensure Product Safety
  
  	
    Share
    Post
    Linkedin

    Email
    Print**Spotlight**

Drug tampering and product
substitution in healthcare facilities
Article by Catherine Hermsen,
Assistant Commissioner
for Criminal Investigations, FDA/OCI
(Journal of Healthcare Protection
Management)

The FDA’s Office of Regulatory Affairs (ORA) uses a robust, risk-based oversight approach to ensure the safety of foods, drugs, and medical products for all Americans.

Our multi-pronged efforts include:

Inspections of food and drug facilities across the United States and world.
	Investigations, including Criminal Investigations, of fraudulent and other criminal activities that threaten public health.
	Laboratory Testing of potentially harmful foods, drugs, and other medical products.
	Screening, with boots on the ground, of all food, drug, and medical product imports into the United States.
	Remote Regulatory Assessments, to ensure industry compliance, remotely and safely, during the COVID-19 pandemic.
	Domestic Mutual Reliance
	Information from capable foreign regulatory partners where there are mutual recognition agreements for drugs,
	Information from trusted foreign regulatory partners under the single audit program for medical devices, and
	Information from trusted foreign regulatory partners where we have systems recognition for foods.Keeping Watch During the COVID-19 Pandemic

The pandemic posed unique challenges to our usual “on the frontlines” regulatory efforts, but ORA readily adapted, both logistically and technologically, to ensure continued protection of public health. We expanded use of our remote surveillance tools and employed other oversight approaches too—all while remaining vigilant about protecting the public, employees at the firms FDA inspects, and our staff from the continued harms of COVID-19.

The Resiliency Roadmap for FDA Inspectional Oversight detailed these efforts and outlined our plans for returning to a more traditional state of inspections and oversight.

And for more on how we exceeded our goals, despite the steep challenges of a global pandemic, we welcome you to read our 2021 annual report.

FY21 Highlights

Exceeded its goals for completing domestic surveillance inspections as outlined in the Resiliency Roadmap’s “base-case scenario.”
	Completed inspections and/or assessments in support of all seven of the identified mission critical applications.
	Made decisions on nearly half of the 68 applications reported as delayed due to a pending inspection or assessment in the Resiliency Roadmap.
	Exceeded its goal related to following up on previous inspections classified as official action indicated (OAI).
	Made more than 1,300 requests to human and animal drug and biological product manufacturers to submit records for review, which supported timely regulatory decisions.
	Conducted more than 130 remote regulatory assessments under the bioresearch monitoring program that were directly used in application decisions.FY21 ORA Accomplishment Highlights
For More Information

Integrated Food Safety System (IFSS)
	An update to the Resiliency Roadmap for FDA Inspectional Oversight (November 2021)
	The Resiliency Roadmap for FDA Inspectional Oversight (May 2021)
	Press release: The Resiliency Roadmap for FDA Inspectional Oversight (May 5, 2021)
	FDA Voices articles on the importation of food and medical products, how we protected patients and consumers from fraud and our inspectional tools during the pandemicSubscribe to receive ORA News and Stories notifications

                                                                                  Content current as of:
      05/22/2023Office of Regulatory Affairs

          
                        FDA/ORA Efforts to Ensure Product Safety
          ORA Recruitment Handouts
          Work at ORA
          Office of Regulatory Affairs Senior Executive Team


                        ORA Program Areas
          Regulatory News, Stories, and Features
          Contact ORA
          ORA FOIA Electronic Reading Room
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop